Brian Weiner

Brian Weiner

Auto-generated profile, based on publicly available information

Brian Weiner

Immuneering Corporation, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2009 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
CCCaroline Colijn
Caroline Colijn
ABAaron Brandes
Aaron Brandes
JZJeremy Zucker
Jeremy Zucker
DLDesmond S. Lun
Desmond S. Lun
BWBrian Weiner
Brian Weiner
JGJames E. Galagan
James E. Galagan
Metabolism is central to cell physiology, and metabolic disturbances play a role in numerous disease states. Despite its importance, the ability to study metabolism at a global scale using genomic technologies is limited. In principle, complete genome sequences describe the range of metabolic reactions that are possible for an organism, but cannot quantitatively describe the behaviour of these reactions. We present a novel method for modeling metabolic states using whole cell measurements of gene expression. Our method, which we call E-Flux (as a combination of flux and expression), extends the technique of Flux Balance Analysis by modeling maximum flux constraints as a function of measured gene expression. In contrast to previous methods for metabolically interpreting gene expression data, E-Flux utilizes a model of the underlying metabolic network to directly predict changes in metabolic flux capacity. We applied E-Flux to Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB). Key components of mycobacterial cell walls are mycolic acids which are targets for several first-line TB drugs. We used E-Flux to predict the impact of 75 different drugs, drug combinations, and nutrient conditions on mycolic acid biosynthesis capacity in M. tuberculosis, using a public compendium of over 400 expression arrays. We tested our method using a model of mycolic acid biosynthesis as well as on a genome-scale model of M. tuberculosis metabolism. Our method correctly predicts seven of the eight known fatty acid inhibitors in this compendium and makes accurate predictions regarding the specificity of these compounds for fatty acid biosynthesis. Our method also predicts a number of additional potential modulators of TB mycolic acid biosynthesis. E-Flux thus provides a promising new approach for algorithmically predicting metabolic state from gene expression data. The ability of cells to survive and grow depends on their ability to metabolize nutrients and create products vital for cell function. This is done through a complex network of reactions controlled by many genes. Changes in cellular metabolism play a role in a wide variety of diseases. However, despite the availability of genome sequences and of genome-scale expression data, which give information about which genes are present and how active they are, our ability to use these data to understand changes in cellular metabolism has been limited. We present a new approach to this problem, linking gene expression data with models of cellular metabolism. We apply the method to predict the effects of drugs and agents on Mycobacterium tuberculosis (M. tb). Virulence, growth in human hosts, and drug resistance are all related to changes in M. tb's metabolism. We predict the effects of a variety of conditions on the production of mycolic acids, essential cell wall components. Our method successfully identifies seven of the eight known mycolic acid inhibitors in a compendium of 235 conditions, and identifies the top anti-TB drugs in this dataset. We anticipate that the method will have a range of applications in metabolic engineering, the characterization of disease states, and drug discovery.

10 February 2009 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
ASAndreas Sandgren
Andreas Sandgren
MSMichael Strong
Michael Strong
PMPreetika Muthukrishnan
Preetika Muthukrishnan
BWBrian K Weiner
Brian K Weiner
GCGeorge Church
George Church
MMMegan B Murray
Megan B Murray
Andreas Sandgren and colleagues describe a new comprehensive resource on drug resistance mutations inM. tuberculosis.

3 October 2008 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
TRT. B. K. Reddy
T. B. K. Reddy
RRRobert Riley
Robert Riley
FWFarrell Wymore
Farrell Wymore
PMPhillip Montgomery
Phillip Montgomery
DDDave DeCaprio
Dave DeCaprio
GSGary K. Schoolnik
Gary K. Schoolnik
The effective control of tuberculosis (TB) has been thwarted by the need for prolonged, complex and potentially toxic drug regimens, by reliance on an inefficient vaccine and by the absence of biomarkers of clinical status. The promise of the genomics era for TB control is substantial, but has been hindered by the lack of a central repository that collects and integrates genomic and experimental data about this organism in a way that can be readily accessed and analyzed. The Tuberculosis Database (TBDB) is an integrated database providing access to TB genomic data and resources, relevant to the discovery and development of TB drugs, vaccines and biomarkers. The current release of TBDB houses genome sequence data and annotations for 28 different Mycobacterium tuberculosis strains and related bacteria. TBDB stores pre- and post-publication gene-expression data from M. tuberculosis and its close relatives. TBDB currently hosts data for nearly 1500 public tuberculosis microarrays and 260 arrays for Streptomyces. In addition, TBDB provides access to a suite of comparative genomics and microarray analysis software. By bringing together M. tuberculosis genome annotation and gene-expression data with a suite of analysis tools, TBDB (http://www.tbdb.org/) provides a unique discovery platform for TB research.

1 July 2010 in Tuberculosis
Verified
Journal Article
Closed access
JGJames E. Galagan
James E. Galagan
PSPeter Sisk
Peter Sisk
CSChristian Stolte
Christian Stolte
BWBrian Weiner
Brian Weiner
MKMichael Koehrsen
Michael Koehrsen
GSGary K. Schoolnik
Gary K. Schoolnik

3 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
IOIsabella Glitza Oliva
Isabella Glitza Oliva
YSYongwoo Dave Seo
Yongwoo Dave Seo
CSChristine N. Spencer
Christine N. Spencer
JWJennifer R. Wortman
Jennifer R. Wortman
EBElizabeth M. Burton
Elizabeth M. Burton
JWJennifer A. Wargo
Jennifer A. Wargo
Gut-microbiota modulation shows promise in improving immune-checkpoint blockade (ICB) response; however, precision biomarker-driven, placebo-controlled trials are lacking. We performed a multicenter, randomized placebo-controlled, biomarker-stratified phase I trial in patients with ICB-naïve metastatic melanoma using SER-401, an orally delivered Firmicutesenriched spore formulation. Fecal microbiota signatures were characterized at baseline; patients were stratified by high versus low Ruminococcaceae abundance prior to randomization to the SER-401 arm (oral vancomycin-preconditioning/SER-401 alone/nivolumab + SER-401), versus the placebo arm [placebo antibiotic/placebo microbiome modulation (PMM)/nivolumab + PMM (NCT03817125)]. Analysis of 14 accrued patients demonstrated that treatment with SER-401 + nivolumab was safe, with an overall response rate of 25% in the SER-401 arm and 67% in the placebo arm (though the study was underpowered related to poor accrual during the COVID-19 pandemic). Translational analyses demonstrated that vancomycin preconditioning was associated with the disruption of the gut microbiota and impaired immunity, with incomplete recovery at ICB administration (particularly in patients with high baseline Ruminococcaceae). These results have important implications for future microbiome modulation trials. Significance: This first-of-its-kind, placebo-controlled, randomized biomarker-driven microbiome modulation trial demonstrated that vancomycin + SER-401 and anti–PD-1 are safe in melanoma patients. Although limited by poor accrual during the pandemic, important insights were gained via translational analyses, suggesting that antibiotic preconditioning and interventional drug dosing regimens should be carefully considered when designing such trials.

1 January 2012 in BMC Genomics
Verified
Journal Article
Open access
PDF file
AMAbigail M McGuire
Abigail M McGuire
BWBrian Weiner
Brian Weiner
SPSang T Park
Sang T Park
IWIlan Wapinski
Ilan Wapinski
SRSahadevan Raman
Sahadevan Raman
JGJames Galagan
James Galagan
The sequence of the pathogen Mycobacterium tuberculosis (Mtb) strain H37Rv has been available for over a decade, but the biology of the pathogen remains poorly understood. Genome sequences from other Mtb strains and closely related bacteria present an opportunity to apply the power of comparative genomics to understand the evolution of Mtb pathogenesis. We conducted a comparative analysis using 31 genomes from the Tuberculosis Database (TBDB.org), including 8 strains of Mtb and M. bovis, 11 additional Mycobacteria, 4 Corynebacteria, 2 Streptomyces, Rhodococcus jostii RHA1, Nocardia farcinia, Acidothermus cellulolyticus, Rhodobacter sphaeroides, Propionibacterium acnes, and Bifidobacterium longum.